A novel association of pyroptosis-related gene signature with the prognosis of hepatocellular carcinoma

被引:6
作者
Li, Yuyao [1 ]
Li, Yue [1 ]
Zhang, Xuemei [1 ]
Duan, Xiangjuan [1 ]
Feng, Hai [1 ]
Yu, Zhuo [2 ]
Gao, Yueqiu [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Infect Dis, Shanghai, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Liver Dis, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
pyroptosis; hepatocettular carcinoma; prognosis; risk model; immune infiltration; CANCER; INHIBITORS; PLK1;
D O I
10.3389/fonc.2022.986827
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Hepatocellular carcinoma (HCC) is one of the global leading lethal tumors. Pyroptosis has recently been defined as an inflammatory programmed cell death, which is closely linked to cancer progression. However, the significance of pyroptosis-related genes (PRGs) in the prognosis of HCC remains elusive. Methods: RNA sequencing (RNA-seq) data of HCC cases and their corresponding clinical information were collected from the Cancer Genome Atlas (TCGA) database, and differential PRGs were explored. The prognostic PRGs were analyzed with univariate COX regression and the least absolute shrinkage and selection operator (LASSO) Cox regression analysis to build a prognostic model in the TCGA training cohort. The predictive model was further validated in the TCGA test cohort and ICGC validation cohort. Differential gene function and associated pathway analysis were performed by Gene ontology (GO) and Kyoto Encyclopedia of Gene and Genomes (KEGG). Single-sample gene set enrichment analysis (ssGSEA) was used to identify distinct immune cell infiltration. The mRNA and protein expression of prognostic PRGs was examined by quantitative RT-qPCR and immunohistochemistry. Results: We identified 46 PRGs that were differentially expressed between normal and HCC tissues in a TCGA cohort, and HCC patients could be well categorized into two clusters associated with distinct survival rates based on expression levels of the PRGs. A three-PRG prognostic model comprising CHMP4A, HMGB1 and PLK1 was constructed in the training cohort, and HCC patients could be classified into the high- and low-risk subgroups based on the median risk score. High-risk patients exhibited shorter overall survival (OS) than low-risk ones, which was validated in the test cohort and ICGC validation cohort. The risk score of this model was confirmed as an independent prognostic factor to predict OS of HCC patients. GO, KEGG and ssGSEA demonstrated the differential immune cell infiltrations were associated with the risk scores. The higher expression of CHMP4A, HMGB1 and PLK1 were validated in HCC compared to normal in vivo and in vitro. Conclusion: The three-PRG signature (CHMP4A, HMGB1, and PLK1) could act as an independent factor to predict the prognosis of HCC patients, which would shed light upon a potent therapeutic strategy for HCC treatment.
引用
收藏
页数:17
相关论文
共 55 条
[1]   Validated gene targets associated with curatively treated advanced serous ovarian carcinoma [J].
Barlin, Joyce N. ;
Jelinic, Petar ;
Olvera, Narciso ;
Bogomolniy, Faina ;
Bisogna, Maria ;
Dao, Fanny ;
Barakat, Richard R. ;
Chi, Dennis S. ;
Levine, Douglas A. .
GYNECOLOGIC ONCOLOGY, 2013, 128 (03) :512-517
[2]   A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets [J].
Bayo, Juan ;
Fiore, Esteban J. ;
Dominguez, Luciana M. ;
Real, Alejandrina ;
Malvicini, Mariana ;
Rizzo, Manglio ;
Atorrasagasti, Catalina ;
Garcia, Mariana G. ;
Argemi, Josepmaria ;
Martinez, Elisabeth D. ;
Mazzolini, Guillermo D. .
JOURNAL OF HEPATOLOGY, 2019, 71 (01) :78-90
[3]   Necroptosis, pyroptosis and apoptosis: an intricate game of cell death [J].
Bertheloot, Damien ;
Latz, Eicke ;
Franklin, Bernardo S. .
CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (05) :1106-1121
[4]   Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma [J].
Cai, Jiabin ;
Chen, Lei ;
Zhang, Zhou ;
Zhang, Xinyu ;
Lu, Xingyu ;
Liu, Weiwei ;
Shi, Guoming ;
Ge, Yang ;
Gao, Pingting ;
Yang, Yuan ;
Ke, Aiwu ;
Xiao, Linlin ;
Dong, Ruizhao ;
Zhu, Yanjing ;
Yang, Xuan ;
Wang, Jiefei ;
Zhu, Tongyu ;
Yang, Deping ;
Huang, Xiaowu ;
Sui, Chengjun ;
Qiu, Shuangjian ;
Shen, Feng ;
Sun, Huichuan ;
Zhou, Weiping ;
Zhou, Jian ;
Nie, Ji ;
Zeng, Chang ;
Stroup, Emily Kunce ;
Zhang, Xu ;
Chiu, Brian C-H ;
Lau, Wan Yee ;
He, Chuan ;
Wang, Hongyang ;
Zhang, Wei ;
Fan, Jia .
GUT, 2019, 68 (12) :2195-2205
[5]   Playing polo during mitosis: PLK1 takes the lead [J].
Combes, G. ;
Alharbi, I. ;
Braga, L. G. ;
Elowe, S. .
ONCOGENE, 2017, 36 (34) :4819-4827
[6]   Tumour evolution in hepatocellular carcinoma [J].
Craig, Amanda J. ;
Von Felden, Johann ;
Garcia-Lezana, Teresa ;
Sarcognato, Samantha ;
Villanueva, Augusto .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (03) :139-152
[7]   Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma [J].
Dufies, Maeva ;
Verbiest, Annelies ;
Cooley, Lindsay S. ;
Ndiaye, Papa Diogop ;
He, Xingkang ;
Nottet, Nicolas ;
Souleyreau, Wilfried ;
Hagege, Anais ;
Torrino, Stephanie ;
Parola, Julien ;
Giuliano, Sandy ;
Borchiellini, Delphine ;
Schiappa, Renaud ;
Mograbi, Baharia ;
Zucman-Rossi, Jessica ;
Bensalah, Karim ;
Ravaud, Alain ;
Auberger, Patrick ;
Bikfalvi, Andreas ;
Chamorey, Emmanuel ;
Rioux-Leclercq, Nathalie ;
Mazure, Nathalie M. ;
Beuselinck, Benoit ;
Cao, Yihai ;
Bernhard, Jean Christophe ;
Ambrosetti, Damien ;
Pages, Gilles .
COMMUNICATIONS BIOLOGY, 2021, 4 (01)
[8]   Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis [J].
Erkes, Dan A. ;
Cai, Weijia ;
Sanchez, Ileine M. ;
Purwin, Timothy J. ;
Rogers, Corey ;
Field, Conroy O. ;
Berger, Adam C. ;
Hartsough, Edward J. ;
Rodeck, Ulrich ;
Alnemri, Emad S. ;
Aplin, Andrew E. .
CANCER DISCOVERY, 2020, 10 (02) :254-269
[9]   Pyroptosis: A new frontier in cancer [J].
Fang, Yuan ;
Tian, Shengwang ;
Pan, Yutian ;
Li, Wei ;
Wang, Qiming ;
Tang, Yu ;
Yu, Tao ;
Wu, Xi ;
Shi, Yongkang ;
Ma, Pei ;
Shu, Yongqian .
BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
[10]   Evolution of Systemic Therapy for Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Zhu, Andrew X. .
HEPATOLOGY, 2021, 73 :150-157